Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood

키워드

참고문헌 (83)

1. Hardy JA, "Alzheimer's disease : the amyloid cascade hypothesis", Science, 256, pp.184~185 (1992)
2. McKhann G, "Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease", Neurology, 34, pp.939~944 (1984)
3. McKhann GM, "The diagnosis of dementia due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease", Alzheimers Dement, 7, pp.263~269 (2011)
4. Ewers M, "Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance", Neurobiol Aging, 33, pp.1203~1214 (2012)
5. Jacova C, "Neuropsychological testing and assessment for dementia", Alzheimers Dement, 3, pp.299~317 (2007)
6. Morris JC, "Clinical dementia rating : a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type", Int Psychogeriatr, 9(Suppl 1), pp.173~176 (1997)
7. O'Bryant SE, "Staging dementia using Clinical Dementia Rating scale sum of boxes scores : a Texas Alzheimer's research consortium study", Arch Neurol, 65, pp.1091~1095 (2008)
8. Lynch CA, "The clinical dementia rating sum of box score in mild dementia", Dement Geriatr Cogn Disord, 21, pp.40~43 (2006)
9. Tombaugh TN, "The mini-mental state examination : a comprehensive review", J Am Geriatr Soc, 40, pp.922~935 (1992)
10. Harvey PD, "Clinical applications of neuropsychological assessment", Dialogues Clin Neurosci, 14, pp.91~99 (2012)
11. Kulas JF, "Indications for neuropsychological assessment", Cleve Clin J Med, 70, pp.785~786 (2003)
12. Dubois B, "Research criteria for the diagnosis of Alzheimer's disease : revising the NINCDS-ADRDA criteria", Lancet Neurol, 6, pp.734~746 (2007)
13. Du AT, "Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease", J Neurol Neurosurg Psychiatry, 71, pp.441~447 (2001)
14. Bottino CM, "Volumetric MRI measurements can differentiate Alzheimer's disease, mild cognitive impairment, and normal aging", Int Psychogeriatr, 14, pp.59~72 (2002)
15. Shivamurthy VK, "Brain FDG PET and the diagnosis of dementia", AJR Am J Roentgenol, 204, pp.W76~W85 (2015)
16. Silverman DH, "Positron emission tomography in evaluation of dementia : Regional brain metabolism and long-term outcome", JAMA, 286, pp.2120~2127 (2001)
17. Saint-Aubert L, "Tau PET imaging : present and future directions", Mol Neurodegener, 12, pp.19~ (2017)
18. Villemagne VL, "Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions", Nat Rev Neurol, 14, pp.225~236 (2018)
19. Anoop A, "CSF biomarkers for Alzheimer's disease diagnosis", Int J Alzheimers Dis, 2010, pp.606802~ (2010)
20. Tapiola T, "Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain", Arch Neurol, 66, pp.382~389 (2009)
21. Jack CR Jr, "NIA-AA Research Framework : toward a biological definition of Alzheimer's disease", Alzheimers Dement, 14, pp.535~562 (2018)
22. Jack CR Jr, "A", T, Neurology, pp.2016, 87[DOI]
23. Shibata M, "Clearance of Alzheimer's amyloid-β1–40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier", J Clin Invest, 106, pp.1489~1499 (2000)
24. van de Haar HJ, "Blood-brain barrier leakage in patients with early Alzheimer disease", Radiology, 281, pp.527~535 (2016)
25. Issaq HJ, "Serum and plasma proteomics", Chem Rev, 107, pp.3601~3620 (2007)
26. O'Bryant SE, "A blood screening test for Alzheimer's disease", Alzheimers Dement(Amst), 3, pp.83~90 (2016)
27. Mehta PD, "Plasma and cerebrospinal fluid levels of amyloid β proteins 1–40 and 1–42 in Alzheimer disease", Arch Neurol, 57, pp.100~105 (2000)
28. Zecca C, "Plasma β-amyloid1–42 reference values in cognitively normal subjects", J Neurol Sci, 391, pp.120~126 (2018)
29. Tatebe H, "Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology : pilot case-control studies including patients with Alzheimer's disease and down syndrome", Mol Neurodegener, 12, pp.63~ (2017)
30. Zetterberg H, "Plasma tau levels in Alzheimer's disease", Alzheimers Res Ther, 5, pp.9~ (2013)
31. Jinny Claire Lee, "Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers", Experimental and Molecular Medicine, 51, pp.1~10 (2019), 생화학분자생물학회[DOI]
32. Thambisetty M, "Blood-based biomarkers of Alzheimer's disease : challenging but feasible", Biomarkers Med, 4, pp.65~79 (2010)
33. Kuo YM, "Amyloid-β peptides interact with plasma proteins and erythrocytes : implications for their quantitation in plasma", Biochem Biophys Res Commun, 268, pp.750~756 (2000)
34. Pencina MJ, "Evaluating the added predictive ability of a new marker : from area under the ROC curve to reclassification and beyond", Stat Med, 27, pp.157~172 (2008)
35. Lalkhen AG, "Clinical tests : sensitivity and specificity", Contin Educ Anaesth Crit Care Pain, 8, pp.221~223 (2008)
36. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, "Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer's Disease”", Neurobiol Aging, 19, pp.109~116 (1998)
37. Pesini P, "Reliable measurements of the β-amyloid Pool in blood could help in the early diagnosis of AD", Int J Alzheimers Dis, 2012, pp.604141~ (2012)
38. Pérez-Grijalba V, "Several direct and calculated biomarkers from the amyloid-β pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment", J Alzheimers Dis, 36, pp.211~219 (2013)
39. Bateman RJ, "Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo", Nat Med, 12, pp.856~861 (2006)
40. Ovod V, "Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis", Alzheimers Dement, 13, pp.841~849 (2017)
41. Yang CC, "Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro", ACS Chem Neurosci, 2, pp.500~505 (2011)
42. Chieh JJ, "Hyper-high-sensitivity wash-free magnetoreduction assay on biomolecules using high-Tc superconducting quantum interference devices", J Appl Phys, 103, pp.014703~ (2008)
43. Lue LF, "Amyloid beta and tau as Alzheimer's disease blood biomarkers : promise from new technologies", Neurol Ther, 6, pp.25~36 (2017)
44. Chiu MJ, "Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease", ACS Chem Neurosci, 4, pp.1530~1536 (2013)
45. Hye A, "Proteome-based plasma biomarkers for Alzheimer's disease", Brain, 129, pp.3042~3050 (2006)
46. Thambisetty M, "Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals", J Alzheimers Dis, 22, pp.1099~1109 (2010)
47. Thambisetty M, "Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease", Arch Gen Psychiatry, 67, pp.739~748 (2010)
48. An SS, "Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42", Alzheimers Res Ther, 9, pp.86~ (2017)
49. An SS, "Differentiating blood samples from scrapie infected and non-infected hamsters by detecting disease-associated prion proteins using multimer detection system", Biochem Biophys Res Commun, 392, pp.505~509 (2010)
50. Wang MJ, "Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease", Alzheimers Res Ther, 9, pp.98~ (2017)
51. Youn YC, "Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer's disease", Alzheimers Res Ther, 11, pp.40~ (2019)
52. De Felice FG, "Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers", Neurobiol Aging, 29, pp.1334~1347 (2008)
53. Sakono M, "Amyloid oligomers : formation and toxicity of Aβ oligomers", FEBS J, 277, pp.1348~1358 (2010)
54. An SS, "inventors; Peoplebio, Inc., assignee. Differential detection of multimeric and monomeric forms of multimer-forming polypeptides", United States patent US 8,026,070 B2, ~ (2011)
55. Kim Y, "Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system", Sci Adv, 5, pp.eaav1388~ (2019)
56. Kim HY, "EPPS rescues hippocampus-dependent cognitive deficits in APP", PS1 mice by disaggregation of amyloid-β oligomers and plaques, 2015, pp.6, 8997~
57. Yoo YK, "A highly sensitive plasma-based amyloid-β detection system through medium-changing and noise cancellation system for early diagnosis of the Alzheimer's disease", Sci Rep, 7, pp.8882~ (2017)
58. Yoo YK, "An enhanced platform to analyse low-affinity amyloid β protein by integration of electrical detection and preconcentrator", Sci Rep, 7, pp.14303~ (2017)
59. Huang Y, "β-amyloid dynamics in human plasma", Arch Neurol, 69, pp.1591~1597 (2012)
60. Roher AE, "Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease", Alzheimers Dement, 5, pp.18~29 (2009)
61. Villemagne VL, "Amyloid imaging with(8F-florbetaben in Alzheimer disease and other dementias", J Nucl Med, 52, pp.1210~1217 (2011)
62. Oh SJ, "Preliminary PET study of 18F-FC119S in normal and Alzheimer's disease models", Mol Pharm, 14, pp.3114~3120 (2017)
63. Park JC, "Plasma tau", amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease, 2019, pp.142, 771~786
64. Wilson DH, "The Simoa HD-1 analyzer : a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing", J Lab Autom, 21, pp.533~547 (2016)
65. Rissin DM, "Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations", Nat Biotechnol, 28, pp.595~599 (2010)
66. Fischer SK, "Emerging technologies to increase ligand binding assay sensitivity", AAPS J, 17, pp.93~101 (2015)
67. Fulton RJ, "Advanced multiplexed analysis with the FlowMetrix system", Clin Chem, 43, pp.1749~1756 (1997)
68. Reslova N, "xMAP technology : applications in detection of pathogens", Front Microbiol, 8, pp.55~ (2017)
69. Park JC, "Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition", Alzheimers Res Ther, 9, pp.20~ (2017)
70. -AV-1451 tau PET data, "Data Brief", 2017, 648~657
71. Braak H, "Staging of Alzheimer's disease-related neurofibrillary changes", Neurobiol Aging, 16, pp.271~278 (1995)
72. Dage JL, "Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort", Alzheimers Dement, 12, pp.1226~1234 (2016)
73. Mattsson N, "Plasma tau in Alzheimer disease", Neurology, 87, pp.1827~1835 (2016)
74. Fagan AM, "Cerebrospinal fluid tau", β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults, 2007, pp.64, 343~349
75. Gómez-Tortosa E, "Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease", Arch Neurol, 60, pp.1218~1222 (2003)
76. Ritchie C, "CSF tau and the CSF tau", Aβ ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment(MCI), 2017, pp.3, CD010803~
77. Olsson A, "Simultaneous measurement of β-amyloid1– 42, total tau, and phosphorylated tau(Thr181)in cerebrospinal fluid by the xMAP technology", Clin Chem, 51, pp.336~345 (2005)
78. Bateman RJ, "Clinical and biomarker changes in dominantly inherited Alzheimer's disease", N Engl J Med, 367, pp.795~804 (2012)
79. Zissimopoulos J, "The value of delaying Alzheimer's disease onset", Forum Health Econ Policy, 18, pp.25~39 (2014)
80. Zemek F, "Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine", Expert Opin Drug Saf, 13, pp.759~774 (2014)
81. Kyunghwa Jo, "The Effect of Cognitive Intervention on Cognitive Improvement in Patients with Dementia", Dementia and Neurocognitive Disorders(대한치매학회지), 17(1), pp.23~31 (2018), 대한치매학회[DOI]
82. 강민주, "Effect of Paper-Based Cognitive Training in Early Stage of Alzheimer's Dementia", Dementia and Neurocognitive Disorders(대한치매학회지), 18(2), pp.62~68 (2019), 대한치매학회[DOI]
83. HeeYang Lee, "Preventive approach for overcoming dementia", Archives of Pharmacal Research, 42(8), pp.647~657 (2019), 대한약학회[DOI]

관련 논문AI추천